Immunohistochemical Study of Uterine Fibroids and Endometrium: The Significance of Hormonal and Cellular Markers for Clinical Practice
https://doi.org/10.52420/umj.25.1.75
EDN: PHQBWB
Abstract
This article presents the results of immunohistochemical studies on the expression of estrogen and progesterone receptors, as well as markers of proliferation and apoptosis (Ki-67, PCNA, Bcl-2, Bax, CD95) in uterine fibroid and endometrial tissues. Additional growth factors, such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin-like growth factor (IGF-1), and the neovascularization marker CD34, are described. Their roles in predicting proliferative activity and fibroid growth are highlighted. Particular attention is paid to the correlation between pathological changes in uterine fibroids and the endometrium for assessing the potential of minimally invasive diagnostic methods in monitoring fibroid dynamics.
Objective is based on the analysis of Russian and international literature, the study aims to outline promising and underexplored pathogenetic mechanisms of uterine fibroid development, investigate the relationship between molecular markers of proliferation and apoptosis in fibroid and endometrial tissues, and evaluate their significance for predicting fibroid growth and developing personalized therapeutic approaches.
Materials and methods. A literature search was conducted for publications related to immunohistochemical and molecular-biological processes in uterine fibroids from 2011 to 2024. The search was performed in the databases PubMed, Google Scholar, Scopus, and eLibrary.ru.
About the Authors
V. V. Tsypushkina
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Victoria V. Tsypushkina — Assistant of the Department of Obstetrics and Gynecology with Medical Genetics Course, Institute of Pediatrics and Reproductive Medicine
Competing Interests:
Author declare the absence of obvious or potential conflict of interest.
M. B. Koval
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Marina V. Koval — Candidate of Sciences (Medicine), Associate Professor of the Department of Obstetrics and Gynecology with Medical Genetics Course, Institute of Pediatrics and Reproductive Medicine
Competing Interests:
Author declare the absence of obvious or potential conflict of interest.
T. A. Oboskalova
Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Tatiana A. Oboskalova — Doctor of Sciences (Medicine), Professor, Department of Obstetrics and Gynecology with Medical Genetics Course, Institute of Pediatrics and Reproductive Medicine
Competing Interests:
Tatiana A. Oboskalova is an editorial board member of Ural Medical Journal; she did not participate in reviewing the material or making a decision about its publication.
References
1. Eyong E, Okon OA. Large uterine fibroids in pregnancy with successful caesarean myomectomy. Case Reports in Obstetrics and Gynecology. 2020;2020:8880296. DOI: https://doi.org/10.1155/2020/8880296.
2. Al Sulaimani R, Machado L, Al Salmi M. Do large uterine fibroids impact pregnancy outcomes? Oman Medical Journal. 2021;36(4):e292. DOI: https://doi.org/10.5001/omj.2021.93.
3. Sevostyanova OYu, Koval MV, Chumarnaya TV, Belomestnov SR, Sevostyanova NE, Oboskalova TA, et al. Analysis of the incidence of uterine fibroid in Yekaterinburg. Tumors of the Female Reproductive System. 2024;20(2):99–104. (In Russ.). DOI: https://doi.org/10.17650/1994-4098-2024-16-2-99-104.
4. Malyshkina DA, Sotnikova NY, Voronin DN, Kalinina AE, Godunova EM, Golubeva MV, et al. Clinical and anamnestic risk factors for the development of uterine leiomyoma in women of reproductive age: A case control study. Gynecology. 2023;25(2):170–176. (In Russ.). DOI: https://doi.org/10.26442/20795696.2023.2.202209.
5. Adamyan LV, Priputnevich TV, Gavrilova TY, Grigorian IE. Uterine fibroids and endometrial microbiota: Is there a relationship? Russian Journal of Human Reproduction. 2022;28(6):164–169. (In Russ.). DOI: https://doi.org/10.17116/repro202228061164.
6. Schukina NA, Buyanova SN, Babunashvili EL, Tikhomirova EV, Zemskova NY, Glebov TA. Current approaches to drug therapy in patients with concomitant proliferative uterine diseases. Russian Bulletin of Obstetrics and Gynecology. 2022;22(6):102–108. (In Russ.). DOI: https://doi.org/10.17116/rosakush202222061102.
7. Aganezova NV, Aganezov SS, Shilo MM. Use of combined hormonal contraceptives in women with uterine fibroids: Opinions of practitioners. Journal of Obstetrics and Women’s Diseases. 2023;72(2):105–112. (In Russ.). DOI: https://doi.org/10.17816/JOWD321247.
8. Kiknadze T, Tevdorashvili G, Muzashvili T, Gachechiladze M, Burkadze G. Histopathological, proliferative, apoptotic and hormonal characteristics of various types of leiomyomas. Georgian Medical News. 2021;(312):119–125. PMID: https://pubmed.gov/33964839.
9. Machado-Lopez A, Simón C, Mas A. Molecular and cellular insights into the development of uterine fibroids. International Journal of Molecular Sciences. 2021;22(16):8483. DOI: https://doi.org/10.3390/ijms22168483.
10. Zannotti A, Greco S, Pellegrino P, Giantomassi F, Delli Carpini G, Goteri G, et al. Macrophages and immune responses in uterine fibroids. Cells. 2021;10(5):982. DOI: https://doi.org/10.3390/cells10050982.
11. Wang W, Zhang W, Li D, Qian R, Zhu L, Liu Y, et al. Lichong decoction inhibits micro-angiogenesis by reducing the expressions of HIF-1α and VEGF in a hysteromyoma mouse model. Journal of Traditional Chinese Medicine. 2020;40(6):928–937. DOI: https://doi.org/10.19852/j.cnki.jtcm.2020.06.005.
12. Adamyan LV, Sonova MM, Arslanyan KN, Loginova ON. Modern aspects of complex treatment of hysteromyoma. Lechashchiy Vrach. 2019;(3):46–51. (In Russ.). EDN: https://elibrary.ru/FPFAHC.
13. Cloud AS, Koohestani F, McWilliams MM, Ganeshkumar S, Gunewardena S, Graham A, et al. Loss of the repressor REST affects progesterone receptor function and promotes uterine leiomyoma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(44):e2205524119. DOI: https://doi.org/10.1073/pnas.2205524119.
14. Ali M, Ciebiera M, Vafaei S, Alkhrait S, Chen HY, Chiang YF, et al. Progesterone signaling and uterine fibroid pathogenesis: molecular mechanisms and potential therapeutics. Cells. 2023;12(8):1117. DOI: https://doi.org/10.3390/cells12081117.
15. Khan KN, Fujishita A, Koshiba A, Ogawa K, Mori T, Ogi H, et al. Expression profiles of E/P receptors and fibrosis in GnRHa-treated and untreated women with different uterine leiomyomas. PLoS One. 2020;15(11):e0242246. DOI: https://doi.org/10.1371/journal.pone.0242246.
16. Tanioka S, Asano R, Wakabayashi R, Hayashi H, Shigeta H. Possible significance of degeneration and decreased expression of progesterone receptor in postmenopausal uterine leiomyoma. BMC Women’s Health. 2022;22(1):346. DOI: https://doi.org/10.1186/s12905-022-01924-6.
17. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. International Journal of Molecular Sciences. 2020;21(24):9739. DOI: https://doi.org/10.3390/ijms21249739.
18. Vitagliano A, Noventa M, Di Spiezio Sardo A, Saccone G, Gizzo S, Borgato S, et al. Uterine fibroid size modifications during pregnancy and puerperium: Evidence from the first systematic review of literature. Archives of Gynecology and Obstetrics. 2018;297(4):823–835. DOI: https://doi.org/10.1007/s00404-017-4621-4.
19. Chill HH, Karavani G, Rachmani T, Dior U, Tadmor O, Shushan A. Growth pattern of uterine leiomyoma along pregnancy. BMC Women’s Health. 2019;19(1):100. DOI: https://doi.org/10.1186/s12905-019-0803-5.
20. Hutchinson-Colas J. Fibroids after menopause: They never stop growing. Menopause. 2021;28(11):1203. DOI: https://doi.org/10.1097/GME.0000000000001858.
21. Shen M, Duan H, Chang Y, Wang S. Growth of surgically confirmed leiomyomas in postmenopausal women: Analysis of the influencing factors. Menopause. 2021;28(11):1209–1213. DOI: https://doi.org/10.1097/GME.0000000000001846.
22. Saad EE, Michel R, Borahay MA. Cholesterol and immune microenvironment: Path towards tumorigenesis. Current Nutrition Reports. 2024;13(3):557–565. DOI: https://doi.org/10.1007/s13668-024-00542-y
23. Sidorova IS, Kogan EA, Unanian AL, Kiselev VI, Ageev MB. Clinical and morphological correlations for different types of uterine myoma growth. Russian Bulletin of Obstetrics and Gynecology. 2019;19(3):29–36. (In Russ.). DOI: https://doi.org/10.17116/rosakush20191903129.
24. Tonoyan NM, Kozachenko IF, Asaturova AV. Immunohistochemical markers of uterine fibroid recurrence. Obstetrics and Gynecology. 2022;(4):123–131. (In Russ.). DOI: https://doi.org/10.18565/aig.2022.4.123–131.
25. Kirschen GW, AlAshqar A, Miyashita-Ishiwata M, Reschke L, El Sabeh M, Borahay MA. Vascular biology of uterine fibroids: Connecting fibroids and vascular disorders. Reproduction. 2021;162(2):R1–R18. DOI: https://doi.org/10.1530/REP-21-0087.
26. Park JY, Chae B, Kim MR. The potential of transforming growth factor-beta inhibitor and vascular endothelial growth factor inhibitor as therapeutic agents for uterine leiomyoma. International Journal of Medical Sciences. 2022;19(12):1779–1786. DOI: https://doi.org/10.7150/ijms.75203.
27. Bashirov EV, Chuprinenko LM, Krutova VA. Proliferative activity and expression of steroid hormone receptors as predictors of leiomyoma recurrence following organ-preserving interventions. Medical Bulletin of the North Caucasus. 2018;13(1.1):35–38. (In Russ.). DOI: https://doi.org/10.14300/mnnc.2018.13010.
28. Voskresenskaya DL, Malyshkina AI, Antsiferova YS. Relationship character of collagen synthesis in uterine leiomyoma tissue with features of tumor growth. Russian Journal of Immunology. 2019;22(2–1):192–193. (In Russ.). EDN: https://elibrary.ru/ZMWUFY.
29. Dobrokhotova YE, Lapina IA, Gomzikova VM, Sorokin YA, Khatagova ET, Allakhverdieva AR, et al. Treatment of uterine fibroid: Focus on endometrial receptivity. A pilot randomized prospective study. Gynecology. 2024;26(4):339–344. (In Russ.). DOI: https://doi.org/10.26442/20795696.2024.4.202982.
30. Teresiński L, Sipak O, Rył A, Masiuk M, Rotter I, Ratajczak W, et al. Assessment of morphological changes and steroid receptors in the uteri of postmenopausal women. Histology and Histopathology. 2019;34(6):631–644. DOI: https://doi.org/10.14670/HH-18-063.
31. Doroha O, Iarotska I, Vitiuk A, Strelko H. Optimization of methods of diagnostics and treatment of submucosal leiomyomas in women of reproductive age. Georgian Medical News. 2019;(297):35–40. PMID: https://pubmed.gov/32011292.
32. Rubisz P, Hirnle L, Kobierzycki C. The immunohistochemical expression of MCM-3,-5, and-7 proteins in the uterine fibroids. Current Issues in Molecular Biology. 2021;43(2):802–817. DOI: https://doi.org/10.3390/cimb43020058.
33. Aleksandrovych V, Gil A, Wrona A. Sex steroid hormone receptors of telocytes: Potential key role in leiomyoma development. Folia Medica Cracoviensia. 2020;60(2):81–95. DOI: https://doi.org/10.24425/fmc.2020.135015. 34. Ishikawa H, Goto Y, Hirooka C, Katayama E, Baba N, Kaneko M, et al. Role of inflammation and immune response in the pathogenesis of uterine fibroids: Including their negative impact on reproductive outcomes. Journal of Reproductive Immunology. 2024;165:104317. DOI: https://doi.org/10.1016/j.jri.2024.104317. 35. Ilina IYu, Dobrokhotova YuE, Burdin DV. Features of the course of pregnancy and childbirth in patients with uterine fibroids after treatment and without it. Russian Journal of Human Reproduction. 2023;29(3):61–69. (In Russ.). DOI: https://doi.org/10.17116/repro20232903161.
34. Arutyunyan NA, Zuev VM, Ischenko AI, Bryunin DV, Khokhlova ID, Dzhibladze TA. Evaluating the efficiency of immunohistochemical methods in diagnosis of endometrial status in women with uterine infertility. Sovremennye tehnologii v medicine (Modern Technologies in Medicine). 2017;9(1):103–108. (In Russ., Eng.). DOI: https://doi.org/10.17691/stm2017.9.1.13.
35. Sun P, Zhang C, Wang W, Ma H. Mechanism of endometrial receptivity affected by fibroids. American Journal of Reproductive Immunology. 2024;92(6):e70022. DOI: https://doi.org/10.1111/aji.70022.
36. Wei W, Wang N, Zhu Y, Liao M, Wang B, Du T, et al. GM–CSF improves endometrial receptivity in a thin endometrium rat model by upregulating HOXA10. Molecular Human Reproduction. 2023;30(1):gaad042. DOI: https://doi.org/10.1093/molehr/gaad042.
37. Zhang Y, Lu M, Han Y, Liu B, Zhao R, Liu P, et al. Deciphering endometrial dysfunction in patients with uterine myoma using endometrial organoids: A pilot study. Reproductive BioMedicine Online. 2024;49(5):104355. DOI: https://doi.org/10.1016/j.rbmo.2024.104355.
38. Makker A, Goel MM, Nigam D, Bhatia V, Mahdi AA, Das V, et al. Endometrial expression of homeobox genes and cell adhesion molecules in infertile women with intramural fibroids during window of implantation. Reproductive Sciences. 2017;24(3):435–444. DOI: https://doi.org/10.1177/1933719116657196.
39. Voropaeva ЕЕ, Kazachkov EL, Miroshnichenko LE, Kazachkova EA. Endometrial dysfunction in women with uterine myoma, associated with chronic inflammatory diseases of uterus and appendages and infertility. Ural Medical Journal. 2016;(5):16–21. (In Russ.). EDN: https://elibrary.ru/WELQMT.
40. Sinclair DC, Mastroyannis A, Taylor HS. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3. The Journal of Clinical Endocrinology & Metabolism. 2011;96(2):412–421. DOI: https://doi.org/10.1210/jc.2010-1450.
41. Tinelli A, Kosmas I, Mynbaev OA, Favilli A, Gimbrizis G, Sparic R, et al. Submucous fibroids, fertility, and possible correlation to pseudocapsule thickness in reproductive surgery. BioMed Research International. 2018;2018:2804830. DOI: https://doi.org/10.1155/2018/2804830.
42. Ishikawa H, Goto Y, Hirooka C, Katayama E, Baba N, Kaneko M, et al. Role of inflammation and immune response in the pathogenesis of uterine fibroids: Including their negative impact on reproductive outcomes. Journal of Reproductive Immunology. 2024;165:104317. DOI: https://doi.org/10.1016/j.jri.2024.104317.
43. Don EE, Mijatovic V, Huirne JAF. Infertility in patients with uterine fibroids: A debate about the hypothetical mechanisms. Human Reproduction. 2023;38(11):2045–2054. DOI: https://doi.org/10.1093/humrep/dead194.
44. de Mezer M, Dolata N, Markowska J, Krzyżaniak M, Naskręt-Grochowalska A, Żurawski J, et al. Immunohistochemical expression of IL-1β, IL-6, and NF-κB in fibroids. Frontiers in Immunology. 2025;16:1571585. DOI: https://doi.org/10.3389/fimmu.2025.1571585.
45. Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, et al. Comprehensive review of uterine fibroids: Developmental origin, pathogenesis, and treatment. Endocrine Reviews. 2022;43(4):678–719. DOI: https://doi.org/10.1210/endrev/bnab039.
46. Saad EE, Michel R, Borahay MA. Immunosuppressive tumor microenvironment and uterine fibroids: Role in collagen synthesis. Cytokine & Growth Factor Reviews. 2024;75:93–100. DOI: https://doi.org/10.1016/j.cytogfr.2023.10.002.
47. Cui A, Huang T, Li S, Ma A, Pérez JL, Sander C, et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature. 2024;625(7994):377–384. DOI: https://doi.org/10.1038/s41586-023-06816-9.
48. Chuang TD, Ton N, Rysling S, Khorram O. In vivo effects of Bay 11–7082 on fibroid growth and gene expression: A preclinical study. Cells. 2024;13(13):1091. DOI: https://doi.org/10.3390/cells13131091.
49. Kali Z, Cagiran FT. Surgical removal of intramural fibroids improves the TNF-α-induced inflammatory events in endometrium. European Review for Medical and Pharmacological Sciences. 2022;26(24):9180–9186. DOI: https://doi.org/10.26355/eurrev_202212_30669.
50. Ciebiera M, Włodarczyk M, Zgliczyńska M, Łukaszuk K, Męczekalski B, Kobierzycki C, et al. The role of tumor necrosis factor α in the biology of uterine fibroids and related symptoms. International Journal of Molecular Sciences. 2018;19(12):3869. DOI: https://doi.org/10.3390/ijms19123869.
51. Luddi A, Marrocco C, Governini L, Semplici B, Pavone V, Capaldo A, et al. Increased expression of neurogenic factors in uterine fibroids. Human Reproduction. 2019;34(11):2153–2162. DOI: https://doi.org/10.1093/humrep/dez182.
52. Zannotti A, Greco S, Pellegrino P, Giantomassi F, Delli Carpini G, Goteri G, et al. Macrophages and immune responses in uterine fibroids. Cells. 2021;10(5):982. DOI: https://doi.org/10.3390/cells10050982.
53. Wang F, Qualls AE, Marques-Fernandez L, Colucci F. Biology and pathology of the uterine microenvironment and its natural killer cells. Cellular & Molecular Immunology. 2021;18(9):2101–2113. DOI: https://doi.org/10.1038/s41423-021-00739-z.
54. Don EE, Middelkoop MA, Hehenkamp WJK, Mijatovic V, Griffioen AW, Huirne JAF. Endometrial angiogenesis of abnormal uterine bleeding and infertility in patients with uterine fibroids: A systematic review. International Journal of Molecular Sciences. 2023;24(8):7011. DOI: https://doi.org/10.3390/ijms24087011.
55. Vitale SG, Valenti G, Cianci A. Crosstalk between transforming growth factor-β3 and microRNA-29c in leiomyoma: Are we stepping forward? Fertility and Sterility. 2019;112(6):1055–1056. DOI: https://doi.org/10.1016/j.fertnstert.2019.08.067.
56. Chuang TD, Khorram O. Mechanisms underlying aberrant expression of miR-29c in uterine leiomyoma. Fertility and Sterility. 2016;105(1):236–245.e1. DOI: https://doi.org/10.1016/j.fertnstert.2015.09.020.
57. Boos D, Chuang TD, Khorram O. The roles of non-coding RNAs in the pathogenesis of uterine fibroids. Cells. 2025;14(16):1290. DOI: https://doi.org/10.3390/cells14161290.
58. Kabodmehri R, Etezadi A, Sharami SH, Ghanaei MM, Hosseinzadeh F, Heirati SFD, et al. The association between chronic endometritis and uterine fibroids. Journal of Family Medicine and Primary Care. 2022;11(2):653–659. DOI: https://doi.org/10.4103/jfmpc.jfmpc_1470_21.
59. Chodankar RR, Murray A, Nicol M, Whitaker LHR, Williams ARW, Critchley HOD. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible. Fertility and Sterility. 2021;116(3):882–895. DOI: https://doi.org/10.1016/j.fertnstert.2021.02.008.
60. Błaszczak-Świątkiewicz K, Krupa A, Mnich E, Elger W, Oettel M, Nair H, et al. Next step in the development of mesoprogestins: The preclinical profile of EC313. Frontiers in Endocrinology. 2023;14:1201547. DOI: https://doi.org/10.3389/fendo.2023.1201547.
61. Tolibova GK. Pathogenetic determinants of endometrial dysfunction in patients with myoma. Journal of Obstetrics and Women’s Diseases. 2018;67(1):65–72. (In Russ.). DOI: https://doi.org/10.17816/JOWD67165-72.
62. Roshchina MO, Bashmakova NV, Chistyakov MA. Evaluation of histological and immunohistochemical changes in the endometrium after uterine artery embolization for uterine fibroids. Obstetrics and Gynecology. 2012;(8/1):20–24. (In Russ.). EDN: https://elibrary.ru/PIIEAT.
63. Whitaker LH, Murray AA, Matthews R, Shaw G, Williams AR, Saunders PT, et al. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Human Reproduction. 2017;32(3):531–543. DOI: https://doi.org/10.1093/humrep/dew359.
64. Yarmolinskaya MI, Kusevitskaya MB, Tsypurdeeva AA, Tolibova KH, Tral TG. Hormonal and molecular mechanisms of selective progesterone receptor modulator effects on the endometrium in uterine leiomyoma therapy. Gynecology, Obstetrics and Perinatology. 2018;17(4):41–50. (In Russ.). DOI: https://doi.org/10.20953/1726-1678-2018-4-41-50.
Review
For citations:
Tsypushkina VV, Koval MB, Oboskalova TA. Immunohistochemical Study of Uterine Fibroids and Endometrium: The Significance of Hormonal and Cellular Markers for Clinical Practice. Ural Medical Journal. 2026;25(1):75–91. (In Russ.) https://doi.org/10.52420/umj.25.1.75. EDN: PHQBWB
Views:
271
JATS XML
Email this article 